Phosphodiesterase type 5 inhibitors in treatment of lower urinary tract dysfunctions

Cover Page

Cite item

Full Text

Abstract

The article provides a review of current data on the pharmacological and pathogenetic principles of the use of selective type 5 PDE inhibitors in patients with lower urinary tract dysfunctions. The mechanisms of the therapeutic action of these drugs for various urinary tract dysfunctions are examined in detail, the leading of which is the improvement of blood circulation and the reduction of ischemia of the pelvic organs.

About the authors

Igor V. Kuzmin

Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: kuzminigor@mail.ru
https://www.ooorou.ru/ru/users/kuzminigor-mail-ru.html

Doctor of Medical Science, Professor, Urology Department

Russian Federation, Saint Petersburg

Abdul Kh. Ajub

Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation

Email: hammad.315@yandex.ru

Postgraduate

Russian Federation, Saint Petersburg

Margarita N. Slesarevskaya

Academician I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Healthcare of the Russian Federation

Email: mns-1971@yandex.ru

Candidate of Medical Science, Senior Research Fellow, Urology Research Center

Russian Federation, Saint Petersburg

References

  1. Sairam K, Kulinskaya E, McNicholas TA, et al. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002;90(9):836-839. https://doi.org/10.1046/j.1464-410x.2002.03040.x.
  2. Braun MH, Sommer F, Haupt G, et al. Lower Urinary Tract Symptoms and Erectile Dysfunction: Co-morbidity or Typical “Aging Male” Symptoms? Results of the “Cologne Male Survey”. Eur Urol. 2003;44(5): 588-594. https://doi.org/ 10.1016/s0302-2838(03)00358-0.
  3. Korneyev I.A., Alekseeva T.A., Al-Shukri S.H., et al. Prevalence and risk factors for erectile dysfunction and lower urinary tract symptoms in russian federation men: analysis from a national population-based multicenter study. Int J Impot Res. 2016;28(2):74-79. https://doi.org/10.1038/ijir.2016.8.
  4. Kok ET, Schouten BW, Bohnen AM, et al. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: The Krimpen Study. J Urol. 2009;181(2):710-716. https://doi.org/10.1016/j.juro.2008.10.025.
  5. Kim S, Jeong JY, Choi YJ, et al. Association between lower urinary tract symptoms and vascular risk factors in aging men: The Hallym Aging Study. Korean J Urol. 2010;51(7):477-482. https://doi.org/ 10.4111/kju.2010.51.7.477.
  6. Корнеев И.А., Алексеева Т.А., Аль-Шукри С.Х., Пушкарь Д.Ю. Симптомы нижних мочевых путей у мужчин Северо-Западного региона Российской Федерации: анализ результатов популяционного исследования // Урологические ведомости. – 2016. – Т. 6. – № 1. – C. 5–9. [Korneyev IA, Alexeeva TA, Al-Shukri SKh, Pushkar DYu. Lower urinary tract symptoms in male population of the Russian Federation North-Western Region: analysis of population study results. Urologicheskie vedomosti. 2016;6(1):5-9 (In Russ.)]. https://doi.org/10.17816/uroved615-9.
  7. Speakman MJ PDE5 inhibitors in the treatment of LUTS. Curr Pharm Des. 2009;15(30):3502-3205. https://doi.org/10. 2174/138161209789207051.
  8. Mouli S, McVary KT. PDE5 inhibitors for LUTS. Prostate Cancer Prostatic Dis. 2009;12(4):316-24. https://doi.org/10.1038/pcan.2009.27.
  9. Hedlund P. Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract — is there a basis for pharmacological targeting of cGMP? World J Urol. 2005;23(6):362-367. https://doi.org/10.1007/s00345-005-0019-1.
  10. Andersson KE. LUTS treatment: future treatment options. Neurourol Urodyn. 2007;26(6):934-947. https://doi.org/ 10.1002/nau.20500.
  11. McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2005;174(4 Pt 1): 1327-1433. https://doi.org/10.1097/01.ju.0000173072.73702.64.
  12. Кузьмин И.В. Патогенез, клиническое течение и лечение гиперактивности мочевого пузыря: Дис. … докт. мед. наук. – Санкт-Петербург, 2007. [Kuzmin IV. Patogenez, klinicheskoe techenie i lechenie giperaktivnosti mochevogo puzyrja. [dissertation]. Saint Petersburg; 2007. (In Russ.)]. Доступно по http://www.dslib.net/nefrologia/avtoreferat-patogenez-klinicheskoe-techenie-i-lechenie-giperaktivnosti-mochevogo.html. Ссылка активна на 23.02.2020.
  13. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non smooth muscle myosin II. J Physiol. 2000;522(Pt 2):177-185. https://doi.org/10.1111/j.1469-7793.2000.t01-2-00177.x.
  14. Rees RW, Ziessen T, Ralph DJ, et al. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int J Impot Res. 2002;14(1):1-7. https://doi.org/10.1038/sj.ijir.3900814.
  15. Seko T, Ito M, Kureishi Y, et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res. 2003;92(4):411-418. https://doi.org/10.1161/01.RES.0000059987.90200.44.
  16. Rajasekaran M, White S, Baquir A, Wilkes N Rho-kinase inhibition improves erectile function in aging male Brown-Norway rats. J Androl. 2005;26(20:182-188. https://doi.org/10.1002/j.1939-4640.2005.tb01084.x.
  17. Barbosa JA, Muracca E, Nakano É, et al. Interactions between lower urinary tract symptoms and cardiovascular risk factors determine distinct patterns of erectile dysfunction: a latent class analysis. J Urol. 2013;190(6):2177-2182. https://doi.org/10.1016/j.juro.2013.05.048.
  18. Azadzoi KM, Tarcan T, Siroky MB, Krane RJ Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit. J Urol. 1999;161(5):1626-1635.
  19. Takahashi N, Shishido K, Sato Y, et al. The association between severity of atherosclerosis and lower urinary tract function in male patients with lower urinary tract symptoms. Low Urin Tract Symptoms. 2012;4(1):9-13. https://doi.org/10.1111/j.1757-5672.2011.00098.x.
  20. Kullmann A, Birder LA, Andersson K-E. Translational Research and Functional Changes in Voiding Function in Older Adults. Clin Geriatr Med. 2015;31(4):535-548. https://doi.org/10.1016/j.cger.2015.06.001.
  21. Thurmond P, Yang J-H, Azadzoi KM. LUTS in pelvic ischemia: a new concept in voiding dysfunction. Am J Physiol Renal Physiol. 2016;310(8): F738-F743 https://doi.org/10.1152/ajprenal.00333.2015.
  22. Бердичевский Б.А., Бердичевский В.Б. Ишемия детрузора. Клинические эффекты // Урология. – 2019. – № 5. – C. 132–135. [Berdichevsky BA, Berdichevsky VB Detrusor ischemia. Clinical effects. Urologiia. 2019;(5):132-135. (In Russ.)]. https://doi.org/10.18565/urology.2019.5.132-135.
  23. Аляев Ю.Г., Есилевский Ю.М., Шмидт Т.Е. и др. Изменения кровообращения в пузырно-уретральном сегменте у мужчин с нейрогенными и ненейрогенными симптомами нижних мочевыводящих путей // Урология. – 2016. – № 6. – С. 17–21. [Alayev YuG, Esilevskiy YuM, Shmidt TE, et al. Alterations in blood circulation of vesicourethral segment in men with neurogenic and non-neurogenic lower urinary tract symptoms. Urologiia. 2016;(6):17-21 (In Russ.)]
  24. Аль-Шукри С.Х., Кузьмин И.В. Качество жизни больных с гиперактивностью мочевого пузыря // Урологические ведомости. – 2011. – Т. 1. – № 1. – С. 21–26. [Al-Shukri SKh, Kuzmin IV. Quality of life in patients with overactive bladder. Urologicheskie vedomosti. 2011;1(1):21-26. (In Russ.)].
  25. Кузьмин И.В. Эпидемиологические аспекты гиперактивного мочевого пузыря и ургентного недержания мочи // Урологические ведомости. – 2015. – Т. 5. – № 3. – C. 30–34. [Kuzmin IV. Epidemiological aspects of overactive bladder and urge urinary incontinence. Urologicheskie vedomosti. 2015;5(3):30-34. (In Russ.)]. https://doi.org/10.17816/uroved5330-34.
  26. Аль-Шукри С.Х., Кузьмин И.В., Амдий Р.Э., и др. Состояние микроциркуляции в стенке мочевого пузыря и клинические проявления гиперактивности мочевого пузыря у женщин // Экспериментальная и клиническая урология. – 2010. – № 2. – С. 52–55. [Al-Shukri SKh, Kuz’min IV, Amdiy RE, et al. Microcirculation in urinary bladder wall and clinical symptoms of overactive bladder in women. Experimental and Clinical Urology. 2010;(2):52-55 (In Russ.)].
  27. Аль-Шукри С.Х., Кузьмин И.В., Слесаревская М.Н., Шабудина Н.О. Внутрипузырная ультразвуковая допплерография в оценке состояния кровотока в стенке мочевого пузыря у женщин с ирритативными симптомами // Регионарное кровообращение и микроциркуляция. – 2014. – Т. 13. – № 1(49). – С. 48–54. [Al-Shukri S, Kuzmin I, Slesarevskaya M, Shabudina N. Intravesical Ultrawave Doppler in assessing blood flow in the bladder wall in women with irritative symptoms. Regional blood circulation and microcirculation. 2014;13(1 49):48-54 (In Russ.)]. https://doi.org/10.24884/1682-6655-2014-13-1-48-54.
  28. Kershen RT, Azadzoi KM, Siroky MB. Blood flow, pressure and compliance in the male human bladder. J Urol. 2002;168(1):121-125.
  29. Кирпатовский В.И., Плотников Е.Ю., Мудрая И.С. и др. Ишемия мочевого пузыря как причина его дисфункции после острой задержки мочи // Экспериментальная и клиническая урология. – 2012. – № 3. – C. 9–13. [Kirpatovskiy VI, Plotnikov EYu, Mudraya IS, et al. Ischemia of the bladder, as the cause of its dysfunction after acute urinary retention. Experimental and Clinical Urology. 2012;(3):9-13 (In Russ.)].
  30. Vince R, Tracey A, Deebel NA, et al. Effects of vesical and perfusion pressure on perfusate flow, and flow on vesical pressure, in the isolated perfused working pig bladder reveal a potential mechanism for the regulation of detrusor compliance. Neurourol Urodyn. 2017;37(2):642-649. https://doi.org/ 10.1002/nau.23362.
  31. Кузьмин И.В., Шабудина Н.О. Патогенетические основы развития диабетической цистопатии // Экспериментальная и клиническая урология. – 2014. – № 4. – С. 92–99. [Kuzmin IV, Shabudina NO Pathogenetic basis development of diabetic cystopathy. Experimental and Clinical Urology. 2014;(4):92-99 (In Russ.)].
  32. Кузьмин И.В., Шабудина Н.О., Аль-Шукри А.С. Симптоматика и клиническое течение цистопатии у больных сахарным диабетом 2 типа // Сахарный диабет. – 2013. – Т. 16. – № 2. – С. 73–76. [Kuzmin IV, Shabudina NO, Al-Shukri AS. Semiology and clinical development of cystopathy in patients with type 2 diabetes mellitus. Diabetes mellitus. 2013;16(2):73-76 (In Russ.)]. https://doi.org/10.14341/2072-0351-3759.
  33. Аль-Шукри С.Х., Кузьмин И.В., Шабудина Н.О. Дисфункции нижних мочевых путей у больных сахарным диабетом // Уральский медицинский журнал. – 2012. – № 3(95). – С. 114–119. [Al-Shukri SH, Kuzmin IV, Shabudina NO. Lower urinary tract dysfunctions in patients with diabetes mellitus. Ural Medical Journal. 2012;(3):114-119. (In Russ.)].
  34. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res. 2003;93(4):280-291. https://doi.org/10.1161/01.RES.0000087541.15600.2B.
  35. Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30(3):292-301. https://doi.org/10.1002/nau.20999.
  36. Cellek S, Cameron NE, Cotter MA, et al. Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Nat Rev Urol. 2014;11(4):231-241. https://doi.org/10.1038/nrurol.2014.53.
  37. Morelli A, Filippi S, Sandner P, et al. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med. 2009;6(6):1594-1608. https://doi.org/10.1111/j.1743-6109.2009.01249.x.
  38. Giuliano F, Ückert S, Maggi M, et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013;63(3):506-516. https://doi.org/10.1016/j.eururo.2012.09.006.
  39. Uckert S, Hedlund P, Andersson KE, et al. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol. 2006;50(6):1194-1207. https://doi.org/ 10.1016/j.eururo.2006.05.025.
  40. Fibbi B, Morelli A, Vignozzi L, et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med. 2010;7 (1 Pt 1):59-69. https://doi.org/10.1111/j.1743-6109.2009.01511.x.
  41. Behr-Roussel D, Oger S, Caisey S, et al. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. Eur Urol. 2010;59(2):272-279. https://doi.org/10.1016/j.eururo.2010.10.03.
  42. Choi H, Bae JH, Shim JS, et al. Mirodenafil prevents bladder dysfunction induced by chronic bladder ischemia in rats. Int Neurourol J. 2015;19(1):19-26. https://doi.org/10.5213/inj.2015.19.1.19.
  43. Porst H, Kim ED, Casabe AR, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol. 2011;60(5):1105-1113. https://doi.org/10.1016/j.eururo.2011.08.005.
  44. Калинина С.Н., Бурлака О.О., Александров М.С., Выдрин П.С. Диагностика и лечение симптомов нижних мочевых путей и эректильной дисфункции у больных доброкачественной гиперплазией предстательной железы // Урологические ведомости. – 2018. – Т. 8. – № 1. – C. 26–33. [Kalinina SN, Burlaka OO, Aleksandrov MS, Vydryn PS Diagnosis and treatment of lower urinary tract symptoms and erectile dysfunction in patients with benign prostate hyperplasia. Urologicheskie vedomosti. 2018;8(1):26-33 (In Russ.)]. 10.17816/uroved8126-33.
  45. Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61(5): 917-925. https://doi.org/10.1016/j.eururo.2012.01.013.
  46. Сивков А.В., Кешишев Н.Г., Ковченко Г.А. Влияние ингибиторов фосфодиэстеразы 5-го типа на симптомы нижних мочевых путей и эректильную функцию у больных ДГПЖ // Экспериментальная и клиническая урология. – 2010. – № 4. – C. 44–49. [Sivkov AV, Keshishev NG, Kovchenko GA. Influence of Phosphodiesterase Type 5 Inhibitors on Lower Urinary Tract Symptoms and Erectile function in Patients with BPH. Experimental and Clinical Urology. 2010;(4):44-49 (In Russ.)]
  47. Камалов А.А., Низов А.Н. Эффективность ингибиторов фосфодиэстеразы 5-го типа в терапии симптомов нижних мочевыводящих путей у пациентов с доброкачественной гиперплазией предстательной железы и сочетанной эректильной дисфункцией // Урология. – 2019. – № 4. – С. 130–134. [Kamalov AA, Nizov AN. Efficiency of phosphodiesterase-5 inhibitors for treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia and concomitant erectile dysfunction. Urologiia. 2019;(4):130-134. (In Russ.)]. https://doi.org/10.18565/urology.2019.4.130-134.
  48. Wang Y, Bao Y, Liu J, et al. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. Low Urin Tract Symptoms. 2018;10(1):84-92. https://doi.org/10.1111/luts.12144.
  49. Gacci, M, Corona G, Salvi M, et al. A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Flone or in Combination with α-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Eur Urol. 2012;61(5):994-1003. https://doi.org/10.1016/j.eururo.2012.02.033.
  50. Сивков А.В., Ромих В.В., Коршунова Е.С., Коршунов М.Н. Применение ингибиторов фосфодиэстеразы 5 типа у пациентов с гиперактивным мочевым пузырем // Экспериментальная и клиническая урология. – 2010. – № 4. – С. 54–59. [Sivkov AV, Romih VV, Korshunova ES, Korshunov MN. Type 5 Phosphodiesterase Inhibitors in Treatment of Patients with Hyperactive Bladder. Experimental and Clinical Urology. 2010;(4):54-59 (In Russ.)]
  51. Васильев А.О., Говоров А.В., Касян Г.Р., Пушкарь Д.Ю. Доброкачественная гиперплазия предстательной железы: возможность применения ингибиторов фосфодиэстеразы 5-го типа // Медицинский Совет. – 2016. – № 19. – С. 109–113. [Vasiliev AO, Govorov AV, Kasyan GR, Pushkar DYu Benign prostatic hyperplasia: a possibility to use type 5 phosphoesterase inhibitors. Meditsinskiy sovet = Medical Council. 2016;(19):109-113 (In Russ)]. https://doi.org/10.21518/2079-701X-2016-19-109-113.
  52. Vignozzi L, Gacci M, Cellai I, et al. PDE5 inhibitors blunt inflammation in human BPH: А potential mechanism of action for PDE5 inhibitors in LUTS. Prostate. 2013;73(13): 1391-1402. https://doi.org/ 10.1002/pros.22686.
  53. Andersson KE. The many faces of impaired bladder emptying. Curr Opin Urol. 2014;24(4):363-369. https://doi.org/ 10.1097/MOU.0000000000000059.
  54. Osman NI, Chapple CR, Abrams P, et al. Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol. 2014;65(2):389-398. https://doi.org/10.1016/j.eururo.2013.10.015.
  55. Chancellor MB. The overactive bladder progression to underactive bladder hypothesis. Int Urol Nephrol. 2014;46(Suppl. 1): S23-27. https://doi.org/10.1007/s11255-014-0778-y.
  56. Аль-Шукри С.Х., Амдий Р.Э., Кузьмин И.В. Снижение сократимости мочевого пузыря у больных доброкачественной гиперплазией предстательной железы // Урологические ведомости. – 2011. – Т. 1. – № 1. – С. 3–8. [Al-Shukri SKh, Amdiy RE, Kuzmin IV. Decrease of urinary bladder contractility in patients with benign prostate hyperplasia. Urologicheskie vedomosti. 2011;1(1):3-8 (In Russ.)].
  57. Аль-Шукри С.Х., Кузьмин И.В., Шабудина Н.О. Состояние уродинамики нижних мочевых путей у больных с диабетической цистопатией // Урологические ведомости. – 2012. – Т. 2. – № 4. – C. 3–7. [Al-Shukri SKh, Kuzmin IV, Shabudina NO. Urodynamics of lower urinary tract in patients with diabetic cystopathy. Urologicheskie vedomosti. 2012;2(4):3-7. (In Russ.)]. https://doi.org/10.17816/uroved243-7.
  58. Gotoh D., Torimoto K, Tatsumi Y, et al. Tadalafil, a phosphodiesterase type 5 inhibitor, improves bladder blood supply and restores the initial phase of lower urinary tract dysfunction in diabetic rats. Neurourol Urodyn. 2018;37(2):666-672. https://doi.org/ 10.1111/luts.12272.
  59. Sekido N, Kida J, Mashimo H, Wakamatsu D, et al. Promising effects of a novel EP2 and EP3 receptor dual agonist, ONO-8055, on neurogenic underactive bladder in a rat lumbar canal stenosis model. J Urol. 2016;196(2):609-616. https://doi.org/10.1016/j.juro.2016.02.064.
  60. Takaoka EI, Kurobe M, Suzuki T, et al. Urethral dysfunction and therapeutic effects of a PDE5 inhibitor (tadalafil) in a rat model of detrusor underactivity induced by pelvic nerve crush injury. Neurourol Urodyn. 2020;39(3):916-925. https://doi.org/10.1002/nau.24310.

Copyright (c) 2020 Kuzmin I.V., Ajub A.K., Slesarevskaya M.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies